DK3411368T3 - Nrf2-aktiverende forbindelser og anvendelser deraf - Google Patents

Nrf2-aktiverende forbindelser og anvendelser deraf Download PDF

Info

Publication number
DK3411368T3
DK3411368T3 DK17704940.0T DK17704940T DK3411368T3 DK 3411368 T3 DK3411368 T3 DK 3411368T3 DK 17704940 T DK17704940 T DK 17704940T DK 3411368 T3 DK3411368 T3 DK 3411368T3
Authority
DK
Denmark
Prior art keywords
activating compounds
nrf2 activating
nrf2
compounds
activating
Prior art date
Application number
DK17704940.0T
Other languages
English (en)
Inventor
Matthew Duncton
Rajinder Singh
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3411368T3 publication Critical patent/DK3411368T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17704940.0T 2016-02-03 2017-02-01 Nrf2-aktiverende forbindelser og anvendelser deraf DK3411368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290853P 2016-02-03 2016-02-03
PCT/US2017/016069 WO2017136453A1 (en) 2016-02-03 2017-02-01 Nrf2 activating compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK3411368T3 true DK3411368T3 (da) 2020-07-13

Family

ID=58018295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17704940.0T DK3411368T3 (da) 2016-02-03 2017-02-01 Nrf2-aktiverende forbindelser og anvendelser deraf

Country Status (11)

Country Link
US (3) US9845311B2 (da)
EP (1) EP3411368B1 (da)
JP (2) JP7202184B2 (da)
CN (1) CN108699034B (da)
CA (1) CA3012702A1 (da)
DK (1) DK3411368T3 (da)
ES (1) ES2803779T3 (da)
HU (1) HUE050141T2 (da)
PL (1) PL3411368T3 (da)
PT (1) PT3411368T (da)
WO (1) WO2017136453A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3411361T3 (da) 2016-02-03 2021-02-01 Rigel Pharmaceuticals Inc Nrf2-aktiverende forbindelser og anvendelser deraf
CN112004808A (zh) * 2018-05-16 2020-11-27 参宿七制药股份有限公司 Nrf2活化性化合物的前药及其用途
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
US8101373B2 (en) 2007-10-12 2012-01-24 Discoverx Corporation β-galactosidase donor fragments
CN103002742B (zh) * 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
WO2013067036A1 (en) * 2011-10-31 2013-05-10 Rutgers, The State University Of New Jersey Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2014145642A2 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
DK3177599T3 (da) 2014-08-04 2020-03-09 Rigel Pharmaceuticals Inc Fumarat-analoger og anvendelser heraf ved behandling af en autoimmun sygdom eller en inflammatorisk sygdom
DK3411361T3 (da) 2016-02-03 2021-02-01 Rigel Pharmaceuticals Inc Nrf2-aktiverende forbindelser og anvendelser deraf

Also Published As

Publication number Publication date
ES2803779T3 (es) 2021-01-29
CN108699034B (zh) 2020-12-11
EP3411368B1 (en) 2020-04-08
HUE050141T2 (hu) 2020-11-30
EP3411368A1 (en) 2018-12-12
JP2019504093A (ja) 2019-02-14
PT3411368T (pt) 2020-07-01
US10941135B2 (en) 2021-03-09
CA3012702A1 (en) 2017-08-10
US20170217932A1 (en) 2017-08-03
JP7202184B2 (ja) 2023-01-11
US20180258070A1 (en) 2018-09-13
JP2022174199A (ja) 2022-11-22
US10647697B2 (en) 2020-05-12
CN108699034A (zh) 2018-10-23
US9845311B2 (en) 2017-12-19
US20200339538A1 (en) 2020-10-29
WO2017136453A1 (en) 2017-08-10
PL3411368T3 (pl) 2020-11-16

Similar Documents

Publication Publication Date Title
IL272232A (en) Glp-1 compositions and uses thereof
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3658148T3 (da) Makrocykliske forbindelser og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3423076T3 (da) Topisk cyclosporinholdige formuleringer og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf